Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML

Kura Oncology, Inc.

Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.
Phase 1 KOMET-007: 5 newly diagnosed patients on ziftomenib+7+3 all achieved CR (100%).
R/R patients on ziftomenib+ven/aza: ORR 53% (8/15); CR/CRh 56% in menin inhibitor-naïve.
No differentiation syndrome, QTc prolongation, or DLTs observed; well-tolerated.
Expects to complete KOMET-001 enrollment by mid-2024; cash runway into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.